ProQR Therapeutics BV (NASDAQ:PRQR) — Market Cap & Net Worth
Market Cap & Net Worth: ProQR Therapeutics BV (PRQR)
ProQR Therapeutics BV (NASDAQ:PRQR) has a market capitalization of $153.80 Million ($153.80 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17660 globally and #4100 in its home market, demonstrating a 13.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProQR Therapeutics BV's stock price $1.67 by its total outstanding shares 105345192 (105.35 Million). Review ProQR Therapeutics BV (PRQR) total liabilities to assess the company's total debt and financial obligations.
ProQR Therapeutics BV Market Cap History: 2015 to 2026
ProQR Therapeutics BV's market capitalization history from 2015 to 2026. Data shows change from $914.40 Million to $175.93 Million (-17.55% CAGR).
Index Memberships
ProQR Therapeutics BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #492 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1732 of 3165 |
Weight: ProQR Therapeutics BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProQR Therapeutics BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProQR Therapeutics BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.77x
ProQR Therapeutics BV's market cap is 14.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $914.40 Million | $9.41 Million | -$20.83 Million | 97.20x | N/A |
| 2016 | $516.19 Million | $2.28 Million | -$39.10 Million | 226.20x | N/A |
| 2017 | $339.74 Million | $-1.53 Million | -$43.64 Million | -222.20x | N/A |
| 2018 | $1.66 Billion | $4.94 Million | -$36.89 Million | 336.44x | N/A |
| 2019 | $1.04 Billion | $1.93 Million | -$56.75 Million | 540.08x | N/A |
| 2020 | $442.45 Million | $1.03 Million | -$46.56 Million | 429.98x | N/A |
| 2021 | $843.81 Million | $1.33 Million | -$60.74 Million | 632.07x | N/A |
| 2022 | $389.78 Million | $3.59 Million | -$64.42 Million | 108.45x | N/A |
| 2023 | $208.58 Million | $6.51 Million | -$28.12 Million | 32.02x | N/A |
| 2024 | $279.16 Million | $18.91 Million | -$27.76 Million | 14.77x | N/A |
Competitor Companies of PRQR by Market Capitalization
Companies near ProQR Therapeutics BV in the global market cap rankings as of June 18, 2026.
Key companies related to ProQR Therapeutics BV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
ProQR Therapeutics BV Historical Marketcap From 2015 to 2026
Between 2015 and today, ProQR Therapeutics BV's market cap moved from $914.40 Million to $ 175.93 Million, with a yearly change of -17.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $175.93 Million | -17.33% |
| 2025 | $212.80 Million | -23.77% |
| 2024 | $279.16 Million | +33.84% |
| 2023 | $208.58 Million | -46.49% |
| 2022 | $389.78 Million | -53.81% |
| 2021 | $843.81 Million | +90.71% |
| 2020 | $442.45 Million | -57.62% |
| 2019 | $1.04 Billion | -37.20% |
| 2018 | $1.66 Billion | +389.30% |
| 2017 | $339.74 Million | -34.18% |
| 2016 | $516.19 Million | -43.55% |
| 2015 | $914.40 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of ProQR Therapeutics BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $153.80 Million USD |
| MoneyControl | $153.80 Million USD |
| MarketWatch | $153.80 Million USD |
| marketcap.company | $153.80 Million USD |
| Reuters | $153.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more